Stock D4S DAIICHI SANKYO CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Daiichi Sankyo Co., Ltd. Deutsche Boerse AG

Equities

D4S

JP3475350009

Market Closed - Deutsche Boerse AG
Other stock markets
 11:43:53 15/05/2024 am IST 		After market 01:31:02 am
31.93 EUR -2.24% Intraday chart for Daiichi Sankyo Co., Ltd. 32.5 +1.79%
04:04pm Merck to present new oncology data CF
08:06am IHH Healthcare Unit Submits Claim Brief Against Daiichi Sankyo in Tokyo Court MT

Summary

  • The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.

Strengths

  • Its core activity has a significant growth potential and sales are expected to surge, according to Standard & Poor's' forecast. Indeed, those may increase by 63% by 2026.
  • The company's profit outlook over the next few years is a strong asset.
  • Thanks to a sound financial situation, the firm has significant leeway for investment.
  • Over the past year, analysts have regularly revised upwards their sales forecast for the company.
  • For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
  • For the last few months, EPS revisions have remained quite promising. Analysts now anticipate higher profitability levels than before.
  • Analysts covering this company mostly recommend stock overweighting or purchase.
  • Over the past four months, analysts' average price target has been revised upwards significantly.
  • Over the past twelve months, analysts' opinions have been strongly revised upwards.

Weaknesses

  • The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 62.02 times its estimated earnings per share for the ongoing year.
  • The company's "enterprise value to sales" ratio is among the highest in the world.
  • In relation to the value of its tangible assets, the company's valuation appears relatively high.
  • The company is highly valued given the cash flows generated by its activity.
  • The company is not the most generous with respect to shareholders' compensation.

Ratings chart - Surperformance

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
DAIICHI SANKYO CO., LTD. Stock Daiichi Sankyo Co., Ltd.
+30.91% 66.36B -
NOVO NORDISK A/S Stock Novo Nordisk A/S
+31.37% 588B
B
JOHNSON & JOHNSON Stock Johnson & Johnson
-2.60% 364B
C+
MERCK & CO., INC. Stock Merck & Co., Inc.
+20.83% 326B
B-
ABBVIE INC. Stock AbbVie Inc.
+5.69% 285B
C+
ASTRAZENECA PLC Stock AstraZeneca PLC
+14.83% 239B
B+
NOVARTIS AG Stock Novartis AG
+9.93% 210B
B-
ROCHE HOLDING AG Stock Roche Holding AG
-6.95% 200B
A+
AMGEN INC. Stock Amgen Inc.
+10.77% 167B
C+
PFIZER, INC. Stock Pfizer, Inc.
+0.10% 161B
C+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. 4568 Stock
  4. D4S Stock
  5. Ratings Daiichi Sankyo Co., Ltd.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW